FDA approves ONGENTYS® ▼ (opicapone)
BIAL announced today that the U.S Food and Drug Administration (FDA) has approved ONGENTYS® (opicapone) as an add-on treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes.
“We are very pleased to achieve this major regulatory milestone for opicapone, which offers patients living with Parkinson´s disease an effective, once-daily adjunctive treatment option to the gold standard levodopa/dopa-decarboxylase inhibitors preparations. This approval is a landmark in BIAL’s ongoing commitment to the quality of life of Parkinson’s patients and their caregivers. We look forward to working with our partner in the U.S., Neurocrine Biosciences, to make this therapy available to patients.” said António Portela, CEO of BIAL.
In February 2017, BIAL and Neurocrine Biosciences entered into an exclusive licensing agreement for the development and commercialization of opicapone in the U.S. and Canada. The commercial launch of opicapone in the U.S. is expected to occur later in 2020.
The FDA approval of opicapone is supported by data from 38 clinical studies, including two multinational Phase III clinical studies (BIPARK-1 and BIPARK-2). In BIPARK-1, a randomized, double-blind placebo- and active-controlled study, approximately 600 patients with Parkinson’s disease and end-of-dose motor fluctuations received once-daily doses of opicapone (5 mg, 25 mg, or 50 mg), placebo or 200 mg of the COMT (catechol-O-methyltransferase) inhibitor entacapone for 14 to 15 weeks as adjunct to levodopa therapy. In BIPARK-2, which followed a similar study design, approximately 400 patients received once-daily doses of opicapone (25 mg or 50 mg) or placebo.
The primary endpoint for both studies was the change from baseline in absolute time in the OFF state, as assessed by patient diaries. The initial study period in each BIPARK was followed by a one year open-label phase during which all eligible patients received treatment with opicapone. Treatment with opicapone 50 mg was found to be superior to placebo in both studies. The beneficial effects of opicapone 50 mg at reducing the time in the OFF state were accompanied by a corresponding increase in time in the ON state without troublesome dyskinesia. Results from both open-label phases indicated a maintenance of effect for patients previously treated with opicapone 50 mg. Overall, opicapone was found to be generally well tolerated. Primary outcomes from the BIPARK-1 study are published in Lancet Neurology1, with the outcomes from the open-label extension phase published in Neurology2. Primary outcomes from the BIPARK-2 study and the open-label extension are published in JAMA Neurology3.
Parkinson's disease is a neurodegenerative, chronic and progressive disease. The clinical manifestations usually start after the age of 50 years (average age for diagnosis is approximately 60 years) and the prevalence is estimated at 300 per 100,000 inhabitants, increasing to 1/100 over the age of 55–60 years.
In the U.S. each year, an estimated 50,000 people are diagnosed with this neurodegenerative disorder and about one million Americans have the condition4. The European Parkinson’s Disease Association (EPDA) estimates that 1.2 million people have Parkinson's disease in the European Union5.
About Opicapone 6
Opicapone is a once-daily, peripherally-acting, third-generation, highly-selective COMT inhibitor.
Opicapone works by decreasing peripheral levodopa’s conversion rate into 3-O-methyldopa, thereby prolonging the duration of levodopa’s effect in reducing the OFF-time period of Parkinson’s and extending the ON-time period.
In June 2016, the European Commission authorized Ongentys®(opicapone) as an adjunct therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilized on those combinations. In Europe opicapone is currently marketed in Germany, United Kingdom, Spain, Portugal and Italy.
Founded in 1924, BIAL's mission is to research, develop and provide therapeutic solutions within the area of health. In the last decades, BIAL has focused strategically on quality, innovation and internationalisation. BIAL is strongly committed to therapeutic innovation, investing more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system. The company expects to introduce new drugs on the market in the coming years, strengthening its international presence based on proprietary drugs and achieving its goal of supplying innovative products to patients worldwide.
For more information on BIAL: www.bial.com
1. Ferreira J., et al. Lancet Neurol. 2016 Feb;15(2):154-165
2. Ferreira J., et al. Neurology. 2018 May 22;90(21):e1849-e185
3. Lees A., et al. JAMA Neurol. 2017 Feb 1;74(2):197-206
4. Parkinson’s News Today. Available at https://parkinsonsnewstoday.com/parkinsons-disease-statistics/. Accessed April 2020
5. ICM Institute. Neurogenerative Diseases. Available at https://icm-institute.org/en/key-figures/. Accessed March 2020
6. Ongentys® EU SMPC. Last updated 22/04/2020.
Date of preparation: April 2020
T. +351 229866100
T. +44 (0) 7799 380801
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Newmont Publishes 2019 Sustainability Report1.6.2020 15:00:00 CEST | Press release
Newmont Corporation (NYSE: NEM, TSX: NGT) (Newmont or The Company) today announced the publication of its 2019 Sustainability Report, Beyond the Mine, a transparent and comprehensive disclosure of the Company’s environmental, social and governance (ESG) performance. “Our sustainability report provides investors and other stakeholders a transparent and detailed look at look at our safety, environmental and social performance,” said Tom Palmer, President and Chief Executive Officer. “In 2019, we completed two transformative transactions whilst enhancing our ESG performance to align with our position as the world’s leading gold company.” Newmont’s 2019 sustainability highlights include: Achieving no workplace fatalities and conducting a global safety culture review, which identified several opportunities to enhance Newmont’s Fatality Risk Management program and improve the way fatality risks are managed Further strengthening management of tailings, whilst enhancing transparency through a
New Western Union research provides insight into the future of international education1.6.2020 15:00:00 CEST | Press release
The Western Union Company (NYSE: WU), a leader in cross-border, cross-currency money movement and payments, today shares a new report on “The Future of International Education,” in partnership with The Future Laboratory. The white paper highlights five new student profiles that will evolve from the shifting attitudes and behaviors of today’s youth. From Hybrid Thinkers to Greener Graduates, this new report predicts how academic institutions should adapt to meet these expectations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200601005162/en/ Meet the students of the future: new student profiles uncovered in “The Future of International Education” (Graphic: Business Wire) The findings come as universities and colleges worldwide are evolving to navigate COVID-19, from moving online, to delaying term dates. Institutions can use the report to ensure the new policies they introduce align with the needs and priorities of interna
Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation1.6.2020 13:00:00 CEST | Press release
Vivet Therapeutics announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s second gene therapy product, VTX-803, for the treatment of Progressive Familial Intrahepatic Cholestasis type 3 (PFIC3). PFIC3 is a rare life-threatening and chronically debilitating condition due to progressive severe liver dysfunction, accompanied by jaundice, portal hypertension, hepatosplenomegaly and failure to thrive. The symptoms of the disease usually appear first in childhood with progressive cholestasis, evolving to hepatic failure, cirrhosis and need for liver transplantation. “We are very pleased to receive these designations which further validate Vivet’s efforts to treat rare inherited metabolic disorders. The FDA and EC have both recognized the unmet need for a safe and effective treatment of PFIC3 and the potential of VTX-803 to address such need. The field of Progressive Familial Intrahepatic Cholest
FDA Issues Emergency Use Authorization for Impella RP as Therapy for COVID-19 Patients with Right Heart Failure1.6.2020 13:00:00 CEST | Press release
The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Impella RP to include patients suffering from COVID-19 related right heart failure or decompensation, including pulmonary embolism (PE). Abiomed (NASDAQ: ABMD) manufactures Impella RP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200601005257/en/ Impella RP is now FDA indicated for COVID-19 related complications, including pulmonary embolism. (Photo: Business Wire) Impella RP is a temporary heart pump that provides circulatory support for patients who develop right side ventricular failure. Five years of pre- and post-market clinical studies support Impella RP’s safety and efficacy. In 2017, Impella RP received FDA approval as safe and effective for treating right ventricular failure in the setting of acute myocardial infarction and after cardiac surgery. Biventricular cardiac support can be provided when Impella RP is
Zynga Enters Into Agreement to Acquire Istanbul-based Peak, Creator of Top Charting Mobile Franchises Toon Blast and Toy Blast1.6.2020 13:00:00 CEST | Press release
Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, today announced it has entered into a definitive agreement to acquire Peak, one of the most globally successful mobile gaming companies, for $1.8 billion. Peak brings a 100-person strong team and two Forever Franchises, Toon Blast and Toy Blast, that have consistently ranked in the top 10 and top 20 U.S. iPhone grossing games for over two years, respectively. These franchises add significant scale to Zynga’s live services and will be an additional driver of margin expansion over the coming years. Peak also enhances Zynga’s new game pipeline with additional projects in early development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200601005142/en/ Zynga Enters Into Agreement to Acquire Istanbul-based Peak, Creator of Top Charting Mobile Franchises Toon Blast and Toy Blast (Graphic: Business Wire) Founded in 2010 by Sidar Sahin, Peak has developed the
bitFlyer Europe and Quazard Partner to Bring First Ever Trading Competition to Botwars Ultimate Trading1.6.2020 06:00:00 CEST | Press release
Leading cryptocurrency exchange bitFlyer, is partnering with crypto-trading game developer Quazard, to bring the first ever gamified trading competition to the Botwars Ultimate Trading universe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200531005005/en/ bitFlyer and Quazard bring the first gamified trading competition to the Botwars Ultimate Trading universe (Graphic: Business Wire) The competition, which launches today, allows Botwars players to compete in a free to enter crypto-trading simulator to win real Bitcoin. This is the first trading competition to launch on Botwars, and the only live trading competition of its type. In Botwars Ultimate Trading, players need to build an army of trading robots (each representing a trade) and lead them into battle to conquer the cryptocurrency markets. Botwars is a real-time, gamified currency trading experience where you will learn new trading skills, unlock powerful new tradin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom